Showing results (511-520 of 525) with videos related to

Sort By:
Pageof 53
The Lancet. Oncology|May 3, 2024
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trialsFamke C Wakkerman, Jiqing Wu, Hein Putter, et al.
Nature Communications|June 25, 2020
Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trialStefanie de Groot, Rieneke T Lugtenberg, Danielle Cohen, et al.
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
The Lancet. Oncology|July 27, 2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Aging Cell|January 5, 2013
Genome-wide linkage analysis for human longevity: Genetics of Healthy Aging StudyMarian Beekman, Hélène Blanché, Markus Perola, et al.
The Lancet. Oncology|December 25, 2025
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trialAnne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 1, 2026
Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trialAnne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 13, 2020
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancerAnne Sophie V M van den Heerik, Nanda Horeweg, Remi A Nout, et al.
The Lancet. Gastroenterology & Hepatology|August 16, 2024
Indocyanine green near-infrared fluorescence bowel perfusion assessment to prevent anastomotic leakage in minimally invasive colorectal surgery (AVOID): a multicentre, randomised, controlled, phase 3 trialRobin A Faber, Ruben P J Meijer, Daphne H M Droogh, et al.
Pageof 53